---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-281531"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:52:21.063059+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics Q3 2025: ORLYNVAH launch nets $0.4M revenue; cash runway extended to Q2 2026

## Summary
- Net product revenue of $0.4M from ORLYNVAH launch in August 2025; 2026 sales guidance $5M-$15M.
- Cash and equivalents $11.0M as of Sep 30, 2025; additional $2.6M raised Oct-Nov 2025 extends runway into Q2 2026.
- GAAP net loss $9.0M ($0.81 diluted EPS); non-GAAP net loss $7.3M vs. $6.1M and $4.8M in Q3 2024.
- SG&A expenses rose to $6.5M from $1.8M YoY due to commercialization; R&D fell to $1.3M.
- Granted patents in China and Mexico covering sulopenem combinations; IDWeek posters presented.

## SEC filing metadata
- accession: 0001193125-25-281531
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/0001193125-25-281531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-20251114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-281531
- JSON: https://secwatch.observer/filing/0001193125-25-281531.json
- Plain text: https://secwatch.observer/filing/0001193125-25-281531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.